Hemostemix Inc. (CVE:HEM – Get Free Report) rose 25% during trading on Wednesday . The stock traded as high as C$0.15 and last traded at C$0.15. Approximately 411,648 shares were traded during trading, a decline of 11% from the average daily volume of 461,633 shares. The stock had previously closed at C$0.12.
Hemostemix Price Performance
The company has a market cap of C$21.86 million, a PE ratio of -4.37 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The stock’s 50-day moving average is C$0.10 and its 200 day moving average is C$0.14.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- What Makes a Stock a Good Dividend Stock?
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- Stock Splits, Do They Really Impact Investors?
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
